Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | CACNA1I | Q9P0X4 | 5/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3598760 | 0.88 | TP53 (0.44) | HTR7CACNA1IKCNH2TP53MAPT | |
| SCHEMBL3594334 | 0.83 | GRIN2B (0.51) | — | |
| SCHEMBL3598379 | 0.80 | CCR5 (0.43) | CXCR3 | |
| SCHEMBL2975120 | 0.79 | — | — | |
| SCHEMBL2975122 | 0.73 | UBE2M (0.33) | CXCR3 | |
| SCHEMBL3593973 | 0.73 | ARG1 (0.51) | CACNA1IKCNH2 | |
| SCHEMBL3594120 | 0.70 | MAPT (0.55) | CACNA1IKCNH2TP53MAPTSMN1; SMN2 | |
| SCHEMBL3593316 | 0.70 | CCR2 (0.67) | CACNA1IKCNH2TP53 | |
| SCHEMBL3592177 | 0.69 | FAAH (0.59) | HTR7 | |
| Hydrochloric Acid SCHEMBL3592266 | 0.69 | CCR2 (0.65) | CACNA1IKCNH2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1720550-B1 | DERIVATIVES OF PIPERIDINYLALKYLCARBAMATES, PREPARATION METHOD THEREOF AND USE OF SAME AS FAAH ENZYME INHIBITORS | SANOFI AVENTIS (FR) | 2009-04-15 | — | — | EP | claimed |
| US-20100279998-A1 | PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | SANOFI-AVENTIS (FR) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100279998-A1 | PIPERIDINYLALKYLCARBAMATE DERIVATIVES, METHODS FOR THEIR PREPARATION AND THE THERAPEUTIC USE THEREOF AS FATTY ACID AMIDO HYDROLASE ENZYME INHIBITORS | FAAH, FAAH2, CNR2 | HTR7 616/4885CACNA1I 882/4885KCNH2 920/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.